ECSP972193A - PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS - Google Patents

PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS

Info

Publication number
ECSP972193A
ECSP972193A ECSP972193A ECSP972193A EC SP972193 A ECSP972193 A EC SP972193A EC SP972193 A ECSP972193 A EC SP972193A EC SP972193 A ECSP972193 A EC SP972193A
Authority
EC
Ecuador
Prior art keywords
tnf
cancer
matrix
treatment
production
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Lawrence Alan Reiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP972193 priority Critical patent/ECSP972193A/en
Publication of ECSP972193A publication Critical patent/ECSP972193A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a derivados basados en fosfinatos que son inhibidores de mataloproteinasas matriciales o de la producción de factor de necrosis tumoral (TNF) y que, como tales, son útiles en el tratamiento de una condición seleccionada del grupo formado por artritis, cáncer, ulceración de tejidos, restenosis, enfermedad peridontal epidermólisis ampollosas, escleritis, otras enfermedades caracterizadas por actividad de metloproteinasas matriciales, SIDA(Sindrome inmunodeficiencia adquirida), sepsis, shock séptico y otras enfermedades que implican la producción de TNF. Además los compuestos de la presente invención se pueden usar en terapia combinada con fármacos antinflamatorios no esteroides y analgésicos standar y combinados con fármacos citotóxicos como adriamicina, daunomicina, cisplatino, etopósido, taxol, taxotero y otros alcaloides con vincristina, en el tratamiento del cáncer.This invention relates to derivatives based on phosphinates that are inhibitors of matrix mataloproteinases or the production of tumor necrosis factor (TNF) and that, as such, are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, peridontal disease, epidermolysis bullosa, scleritis, other diseases characterized by activity of matrix metloproteinases, AIDS (acquired immunodeficiency syndrome), sepsis, septic shock, and other diseases that involve the production of TNF. Furthermore, the compounds of the present invention can be used in combination therapy with non-steroidal anti-inflammatory drugs and standard analgesics and combined with cytotoxic drugs such as adriamycin, daunomycin, cisplatin, etoposide, taxol, taxoter and other vincristine alkaloids, in the treatment of cancer.

ECSP972193 1997-07-18 1997-07-18 PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS ECSP972193A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP972193 ECSP972193A (en) 1997-07-18 1997-07-18 PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP972193 ECSP972193A (en) 1997-07-18 1997-07-18 PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP972193A true ECSP972193A (en) 1998-09-22

Family

ID=42043024

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP972193 ECSP972193A (en) 1997-07-18 1997-07-18 PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS

Country Status (1)

Country Link
EC (1) ECSP972193A (en)

Similar Documents

Publication Publication Date Title
CO4890852A1 (en) MATRICIAL METALOPROTEASE INHIBITORS BASED ON PHOSPHYTES
BR9714266A (en) Cyclic sulfone derivatives.
AR009292A1 (en) DERIVATIVES OF ACID ARILSULFONILAMINO HIDROXAMICO, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
EA199900641A1 (en) Derivatives of arylsulfonylhydroxamic acid
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
AR069374A2 (en) VALSARTAN SALTS, PROCESS FOR MANUFACTURING, PHARMACEUTICAL COMPOSITIONS AND USE OF SALES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE LOCK OF THE AT1 RECEIVER.
BR0307796A (en) Tricyclic Pyrazole Derivatives for the Treatment of Inflammation
UY25992A1 (en) PROCEDURE FOR PREPARING TACE INHIBITORS (TUMOR NECROSIS ALPHA FACTOR CONVERSING ENZYME)
GT200100183A (en) DERIVATIVES OF QUINOLINA AND QUINAZOLINA.
ES2178724T3 (en) ARILSULFONAMIDE ALPHA-SUBSTITUTED HYDROXAMIC ACIDS AS INHIBITORS OF ALFA TUMOR NECROSIS FACTOR AND MATRIX METALOPROTEINASES.
CY1113160T1 (en) ARYLURIA COMPOUNDS IN CONNECTION WITH OTHER CELLULAR OR CELLULAR MEDICINES FOR HUMAN CANCER TREATMENT
CY1110067T1 (en) INDOLINASE SUBSTITUTES IN SECTION 6, PRODUCING THESE AND USING THESE AS MEDICINES
CY1106125T1 (en) INDAZOLILU SUBSTITUTED PYRROLINE COMPOUNDS AS KINASE INHIBITORS
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
GT200500229A (en) ORGANIC COMPOUNDS
BR0315942A (en) Treatment of diseases and conditions mediated by increased phosphorylation
ECSP066458A (en) 6 - [(REPLACED) PHENYL] TRIAZOLOPIRIMIDINAS AS ANTICANCER AGENTS
ECSP972193A (en) PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS
ES2192878T3 (en) 4,5-AZOLO-OXINDOLS.
DK1181286T3 (en) 3- (arylsulfonylamino) -tetrahydropyran-3-carboxylic acid hydroxamides
ECSP982394A (en) ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES
ECSP972233A (en) DERIVATIVES OF ACID ARILSULFONILAMINO HIDROXAMICO
DE502004007950D1 (en) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
UY32230A (en) DIFENILUREAS (OMEGA) - REPLACED CARBOXIARILICS AS INHIBITORS OF RAF-QUINASA
ECSP993100A (en) HYDROXY ACID DERIVATIVES - HYDROXAMIC PIPECOLATE